News Daily News SWEDEHEART Affirms SAVR’s Long-term Benefits in Young, Low-Risk AS L.A. McKeown November 30, 2021
Presentation TCT 2021 PARTNER 3: Two-Year Economic Outcomes From a Randomized Trial of TAVR vs. SAVR in Patients at Low Surgical Risk Presenter: David Cohen November 05, 2021
News Daily News Infective Endocarditis Rare After AVR, but Often a Killer When It Occurs Michael O'Riordan October 01, 2021
News Daily News EXPLANT-TAVR: Data Spur Conversation About Balancing Risk and Lifetime Management L.A. McKeown September 22, 2021
News Daily News Excluded From Pivotal Trials, Low-risk Complex AS Patients Warrant Caution L.A. McKeown January 22, 2021